Who
Maria Palasis
Director
Company insider
Files Form 4 as: Director, Beta Bionics; Principal Executive Officer, Lyra Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $105K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 30 Apr 2020
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Jul 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Code A | —16,965 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Code A | —16,965 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | Lyra TherapeuticsMedical Devices | SEC FORM 4 Code D | —2,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | Lyra Therapeutics | SEC FORM 4 Code D | —2,000 at $0.00 | filing |
| 13 Jan 2026filed 14 Jan 2026 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Code A | —3,997 at $0.00 | filing |
| 13 Jan 2026filed 14 Jan 2026 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Code A | —3,997 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | Lyra TherapeuticsMedical Devices | SEC FORM 4 Sold | $5,7261,702 at $3.36 | filing |
| 6 Jan 2026filed 8 Jan 2026 | Lyra Therapeutics | SEC FORM 4 Sold | $5,7191,702 at $3.36 | filing |
| 1 Dec 2025filed 2 Dec 2025 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Sold | $27K906 at $29.33 | filing |
| 1 Dec 2025filed 2 Dec 2025 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Sold | $15K500 at $29.96 | filing |
| 31 Oct 2025filed 5 Nov 2025 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Sold | $35K1,287 at $26.86 | filing |
| 31 Oct 2025filed 5 Nov 2025 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Sold | $3,267119 at $27.45 | filing |
| 1 Oct 2025filed 3 Oct 2025 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,667 at $0.00 | filing |
| 10 Jul 2025filed 14 Jul 2025 | Lyra Therapeutics | SEC FORM 4 Sold | $14K1,565 at $8.91 | filing |
| 15 Mar 2025filed 18 Mar 2025 | BBNX Beta BionicsMedical Devices | SEC FORM 4 Code A | —11,247 at $0.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | BBNX Beta Bionicsoption or derivative · Medical Devices | SEC FORM 4 Code A | —9,137 at $0.00 | filing |
| 8 Jan 2025filed 10 Jan 2025 | Lyra Therapeutics | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 9 Dec 2024filed 11 Dec 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —183,333 at $0.00 | filing |
| 16 Oct 2024filed 18 Oct 2024 | Lyra Therapeutics | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 18 Mar 2024filed 20 Mar 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
News
BBNX DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNXBBNX · wallstreet-online.de · 22 Oct 2026BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026BBNX · prnewswire.com · 20 Oct 2026Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ:BBNX) ...BBNX · pr-inside.com · 19 Oct 2026
0 headlines in the last 90 days name Maria Palasis; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.